Clinical applications of stem cell-derived exosomes.
Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. · 2024
Read Clinical applications of stem cell-derived exosomes. by Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10784577.txt.
Introduction
Tan and colleagues survey a cell-free option for healing in this 2024 review. Stem cells can help treat some diseases, but their use in surgery has real limits. Exosomes are tiny sacs that stem cells release, and they carry some of the same healing signals. Unlike live cells, these sacs do not trigger immune rejection and carry no risk of forming tumours.
Drawing on five years of studies, the review covers uses across many fields of surgery. These range from bone and brain surgery to heart, eye, and skin work. Exosomes from bone marrow, fat, nerve, and other stem cells each show promise for distinct problems. The authors urge surgeons, nano-scale drug experts, and stem cell scientists to work together on trials. They present the sacs as a safer path to the gains of stem cell care.
Catalog record
| CREATOR | Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 160 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Clinical applications of stem cell-derived exosomes By Fei Tan, Xuran Li, Zhao Wang, Jiaojiao Li, Khawar Shahzad, Jialin Zheng Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-023-01704-0 ABSTRACT Abstract Although stem cell-based therapy has demonstrated considerable potential to manage certain diseases more successfully than conventional surgery, it nevertheless comes with inescapable drawbacks that might limit its clinical translation. Compared to stem cells, stem cell-derived exosomes possess numerous advantages, such as non-immunogenicity, non-infusion toxicity, easy access, effortless preservation, and freedom from tumorigenic potential and ethical issues. Exosomes can inherit similar therapeutic effects from their parental cells such as embryonic stem cells and adult stem cells through vertical delivery of their pluripotency or multipotency. After a thorough search and meticulous dissection of relevant literature from the last five years, we present this comprehensive, up-to-date, specialty-specific and disease-oriented review to highlight the surgical application and potential of stem cell-derived exosomes. Exosomes derived from stem cells (e.g., embryonic, induced pluripotent, hematopoietic, mesenchymal, neural, and endothelial stem cells) are capable of treating numerous diseases encountered in orthopedic surgery, neurosurgery, plastic surgery, general surgery, cardiothoracic surgery, urology, head and neck surgery, ophthalmology, and obstetrics and gynecology. The diverse therapeutic effects of stem cells-derived exosomes are a hierarchical translation through tissue-specific responses, and cell-specific molecular signaling pathways. In this review, we highlight stem cell-derived exosomes as a viable and potent alternative to stem cell-based therapy in managing various surgical conditions. We recommend that future research combines wisdoms from surgeons, nanomedicine practitioners, and stem cell researchers in this relevant and intriguing research area. Subject terms: Regeneration, Preclinical research, Diseases INTRODUCTION Stem cells are a population of undifferentiated cells with unique abilities to self-renew and recreate functional tissues. They are primarily classified by their differentiation potential, origin and lineage progression. According to their potency, stem cells can be totipotent, pluripotent, multipotent, oligopotent and unipotent.1 Stem cells exist both in embryos and adult cells. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are best examples of pluripotent stem cells,2 whereas adult multipotent stem cells are exemplified by hematopoietic stem cells (HSCs),3 mesenchymal stem cells (MSCs),4 neural stem cells (NSCs),5 and endothelial stem/progenitor cells (EPCs)6 (Fig. 1a). All these subtypes of stem cells have been extensively trialed for the treatment of human diseases. [Figure: Illustration of the upstream measures of exosome therapy (figure generated using Autodesk 3ds Max 2023). a production and purification of exosomes (MSCs and NSCs are used as examples for multipotent stem cells). b content of natural exosomes. c modification of exosomes. (BM bone marrow, DC dendritic cell, IAC immunoaffinity chromatography, iPSC induced pluripotent stem cell, MHC major histocompatibility complex, miRNA microRNA, MSC mesenchymal stem cell, MVB multivesicular body, NSC neural stem cell, SEC size-exclusion chromatography, UC umbilical cord)] Stem cell-based therapy, as a modality of regenerative medicine, has generated tremendous attention, as it offers new options for patients suffering from previously incurable diseases. Subsequently, thousands of related clinical trials have been registered, covering a wide spectrum of medical problems, such as musculoskeletal and neurological disorders, immune diseases, hematological dysfunctions, and degenerative conditions.7 However, some trials have failed to show any benefit in the clinic. This is likely due to the inevitable limitations of stem cell therapy, such as infusion toxicity, immunogenicity, tumorigenic potentials and ethical issues.8 Exosome, secreted by almost all cell types including stem cells (Fig. 1a), has been posited as a safer and more versatile alternative to stem cell therapy.9 Exosomes are nanoscale, spherical, and lipid bi-layered single membrane extracellular vesicles, which act as intercellular messengers.10 Exosomes have been regarded as miniature versions of their parental cells, partially because exosomes from a certain cell type provide cell-specific or unique sets of biomolecules. In addition, the stem cells have been found to function in a paracrine fashion through their soluble secretome including exosomes.11 In other words, stem cell-derived exosomes (SC-Exo) inherit similar therapeutic effects from their parental cell of origin, e.g., anti-inflammation, immunomodulation and tissue regeneration.12 Collectively, stem cell-derived exosomes are a potent surrogate for stem cell therapy without exhibiting the disadvantages their cellular counterparts present13 (Table 1). [Table: The comparison between stem cell therapy and stem cell-derived exosome therapy] Prior to clinical applications, exosomes must be prepared and optimized in terms of production, purification, and modification (Sections 2.3 and 2.4). A wide range of medical reviews analyzing these upstream measures of exosome therapy have been published in recent years. Nevertheless, some research avenues remain under-investigated: in particular, systematic investigation dedicated to downstream clinical applications is lacking, especially from a surgical perspective. Tissues that have been damaged, whether by disease or a surgeon’s scalpel, respond by inflammatory and regenerative dynamics,14 making surgery a perfect arena for stem cell-derived exosome therapy.15 Stem cell-derived exosomes inherit similar therapeutic effects from their parental cell of origin, e.g., tissue regeneration, anti-inflammation and immunomodulation.12,16–18 In this work, we will dissect relevant publications from the last five years in order to present a comprehensive, up-to-date, specialty-specific and disease-oriented review (Fig. 2). Our aim is to bridge the gap that currently exists between surgeons, nanomedicine practitioners, and stem cell researchers. [Figure: Illustration of the downstream surgical applications of exosome therapy (figure generated using Adobe Photoshop 2023 and Adobe Illustrator 2023). The therapeutic effects of exosomes are a hierarchical translation through disease-specific tissue responses, tissue-specific cellular alterations, and cell-specific molecular signaling pathways] GENERAL BACKGROUND OF EXOSOMES AND EXOSOME THERAPY Biogenesis, composition, and uptake of exosomes Exosomes differ from other types of primary extracellular vesicles (e.g., apoptotic bodies and microvesicles) in terms of size, content, and production mechanism.19 The most popularly accepted mechanism of exosome formation, i.e., an endosomal route, is as follows (Fig. 1a). The initial endosomes are produced by cell membrane invagination during which the bioactive substances begin to accumulate within the early sorting endosomes. The late sorting endosomes then form multivesicular bodies (MVBs) after a second indentation. Finally, the MVBs fuse with the cell membrane, releasing the carried exosomes to the outside. Non-endosomal route of exosome biogenesis, such as plasma membrane budding, has also been reported.20 As the three major exosome databases (i.e., ExoCarta, Vesiclepedia, and EVpedia) summarize, exosomes contain numerous molecules, including proteins, glycoconjugates, lipids, nucleic acids, metabolites, and other bioactive substances (Fig. 1b). The examples of each category and the corresponding functions have been thoroughly reviewed elsewhere.21,22 On the one hand, exosomes comprise a complex protein network including external proteins (e.g., tetraspanins, antigen-presenting complexes, and adhesion molecules) and internal proteins (e.g., heat shock proteins, ESCRT machinery, cytokines and chemokines, and membrane transporters).23 On the other hand, as the most abundant in human exosomal nucleic acids, microRNA (mRNA) could participate in hematopoiesis, exocytosis, and nerve and vascular regeneration through exosome-mediated cellular communication.24 There are various uptake mechanisms once exosomes reach the recipient cell, all of which can be categorized into membrane fusion, receptor interaction, and internalization21 (Fig. 1b). Finally, the exosomal cargos are released into the cytoplasm, the process of which depends on the source of the exosome, nature of the cargo, and the metabolic state of the recipient cell.25 The entire lifecycle from exosome biogenesis to uptake and intracellular signaling can be tracked using fluorescent, luminescent, and radioactive techniques.26,27 Source and classification of exosomes Depending on whether exosomes have been artificially modified, they are broadly classified into